Patents
Literature
31 results about "Treatment-resistant depression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment-resistant depression (TRD) is a term used in clinical psychiatry to describe a condition that affects people with major depressive disorder (MDD) who do not respond adequately to a course of appropriate antidepressant medication within a certain time. Typical definitions of TRD vary, and they do not include a resistance to psychological therapies. Inadequate response has traditionally been defined as no clinical response whatsoever (e.g. no improvement in depressive symptoms). However, many clinicians consider a response inadequate if the person does not achieve full remission of symptoms. People with treatment-resistant depression who do not adequately respond to antidepressant treatment are sometimes referred to as pseudoresistant. Some factors that contribute to inadequate treatment are: early discontinuation of treatment, insufficient dosage of medication, patient noncompliance, misdiagnosis, and concurrent psychiatric disorders. Cases of treatment-resistant depression may also be referred to by which medications people with TRD are resistant to (e.g.: SSRI-resistant). In TRD adding further treatments such as psychotherapy, lithium, or aripiprazole is weakly supported as of 2019.
Bupropion dosage forms with reduced food and alcohol dosing effects
ActiveUS20250268891A1Nervous disorderHydroxy compound active ingredientsIngested foodTreatment-resistant depression
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Methods for treating treatment resistant depression
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Evaluation system based on intracranial magnetic stimulation treatment effect of intracranial depression
The invention provides an evaluation system based on a transcranial magnetic stimulation treatment effect of refractory depression, and belongs to the field of transcranial magnetic stimulation treatment evaluation. The problem that the objectivity and interpretability of an evaluation result are insufficient due to the fact that multi-modal data are not effectively integrated in the prior art is solved. The system comprises a neural navigation module which is used for determining an individualized transcranial magnetic stimulation target spot through a resting state functional magnetic resonance imaging technology and a remote isolation effect principle; the periodic treatment module is used for carrying out cranial magnetic stimulation frequency setting by adopting an alternate theta burst stimulation scheme; the data acquisition and processing module is used for acquiring multi-modal data before and after treatment and performing feature extraction; and the treatment evaluation module is used for establishing a multi-modal fusion curative effect prediction model through a support vector machine, and the model is used for evaluating the treatment effect and predicting the symptom relieving degree after being trained by a training data set. The method is mainly used in data evaluation field.
Owner:QIQIHAR MEDICAL UNIVERSITY
Tryptamine prodrugs
ActiveJP2025143280AOrganic active ingredientsPowder deliveryPost-pregnancy depressionGeneralized anxiety
To provide a compound useful for the treatment of mental disorders, such as a depressive condition including unipolar and bipolar depressive conditions, for example, but not limited to, depression, depression from generalized anxiety, major depression, treatment resistant depression, and postpartum depression.SOLUTION: The present invention provides a tryptamine prodrug compound represented by the following formula.SELECTED DRAWING: Figure 1
Owner:REUNION NEUROSCIENCE INC
Uses of JAK Inhibitors in the Management of Inflammation-Associated Depression and Central Nervous System (CNS) Pathologies
This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.
Owner:EMORY UNIVERSITY +1
Automated diagnosis and treatment of mood and psychotic disorders using membrane protein clustering
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC
Methods of treating treatment resistant depression
PCT designated stageWO2026030301A1Nervous disorderPharmaceutical delivery mechanismDosing regimenRegimen
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Subcutaneous formulations comprising psilocybin derivatives
PCT designated stageWO2026017869A1Organic active ingredientsNervous disorderSubcutaneous injectionNeuropsychiatric disease
The present disclosure provides stable liquid formulations comprising Compound (1), or a pharmaceutically acceptable salt of Compound (1), and one or more pharmaceutically acceptable excipients. The liquid formulation may comprise a pH buffered aqueous solution, and optionally a pH modifier and / or a tonicity agent. Also provided herein are methods of delivering the formulation via parenteral administration (e.g., subcutaneous injection), and methods of using the formulation in the treatment of neuropsychiatric diseases (e.g., treatment resistant depression).
Owner:COMPASS PATHFINDER LTD
Antidepressant compound 4-methyl-6-methoxycoumarin
PendingCN121754531ANervous disorderHeterocyclic compound active ingredientsTherapeutic effectSleep wake
The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.
Owner:SUZHOU UNIV
Induction regimen for administering 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
The present invention relates to a dosing regimen of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, also known as ketamine, or a derivative thereof for use in the treatment of depression, in particular treatment resistant depression.
Owner:HMNC HOLDINGS
Methods of diagnosing and treating mood and psychotic disorders using lymphocyte biomarkers
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC +3
Methods of diagnosing and treating mood and psychotic disorders using lymphocyte biomarkers
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC +3
A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome
PCT designated stageWO2026015878A1Nervous disorderEster active ingredientsDepressed - symptomCombination therapy
The invention provides a composition and method of treating depression by administering to a patient in need of such treatment a combination of pindolol and fenofibrate in a ratio of about 3mg pindolol / 33mg fenofibrate and is useful in augmentation to treatment of depression.
Owner:MINDX THERAPEUTICS INC
Automated diagnosis and treatment of mood and psychotic disorders using membrane protein clustering
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC
Monoacylglycerol Lipase Modulators
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
Owner:JANSSEN PHARMA NV
Treatment for refractory depression with glycyrrhizin
Owner:MURCK HARALD WESTFIELD
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Use of pharmaceutical composition
PCT designated stageWO2026052068A1Organic active ingredientsNervous disorderPharmaceutical drugPharmaceutical Substances
The present disclosure relates to use of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the present disclosure is used for treating inflammatory depression, wherein the pharmaceutical composition comprises: (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition of the present disclosure is directed to inflammatory depression (especially inflammatory treatment-resistant depression and anhedonia depression).
Owner:PRECISION BRAIN SCIENCE BIOTECHNOLOGY (SUZHOU) CO LTD
Pharmaceutical composition and application thereof
The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises two active ingredients: (1) votioxetine or a pharmaceutically acceptable salt thereof; and (2) olanzapine, the weight ratio of the vothioxetine or the pharmaceutically acceptable salt thereof to the olanzapine is (6-50): (3-6), preferably (9-50): 6, and the weight of the two active ingredients is calculated in a free form. The invention further relates to a pharmaceutical preparation prepared from the composition and application of the pharmaceutical composition and the pharmaceutical preparation in prevention and / or treatment of depression and other diseases, and the application comprises the step of applying an effective amount of the pharmaceutical composition or the pharmaceutical preparation to a patient in need. The pharmaceutical composition disclosed by the invention can be used for treating bipolar affective disorder, refractory depression and anxiety and improving cognition, and also has the advantages of small side effect and good patient compliance.
Owner:SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD
Application of pharmaceutical composition
PendingCN120939027AOrganic active ingredientsNervous disorderPharmaceutical drugPharmaceutical Substances
The present disclosure relates to uses of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the invention is used for treating inflammatory depression, and the pharmaceutical composition comprises (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition disclosed by the invention is used for treating inflammatory depression (especially inflammatory refractory depression and pleasant sensation deficiency type depression).
Owner:PRECISION BRAIN SCIENCE BIOTECHNOLOGY (SUZHOU) CO LTD
Galanin (1-15) and fluoxetine in the treatment of treatment-resistant depression
PCT designated stageWO2026013329A1Organic active ingredientsNervous disorderDepressantDepressed - symptom
Galanin (1-15) and fluoxetine in the treatment of treatment-resistant depression, GAL (1-15) in combination with a seratonin reuptake inhibitor, preferably fluoxetine, for use in the treatment of treatment-resistant depression, and a composition comprising same.
Owner:UNIV DE MALAGA
Pharmacogenomic decision support for modulators of NMDA, glycine and AMPA receptors
The present invention relates to pharmacogenomic decision support for modulators of NMDA, glycine and AMPA receptors. Used for identifying diagnosed as having therapeutically resistant or refractory depression, pain or other clinical indications and suitable for accepting N-methyl-d-aspartate receptor antagonists, glycine receptor beta (GLRB) modulators or alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPAR) Methods for patients of therapy include determining an appropriate drug, an optimal dose per patient, and determining which patients are not suitable for receiving the therapy. Pharmacogenomic clinical decisions support the determination of a combination of targeted single nucleotide polymorphisms and clinical values, or targeted single nucleotide polymorphisms, targeted ketamine-specific expansion and contraction of topologically associated domains, and clinical values. The methods described herein allow for more efficient determination of which patients will experience drug efficacy and which patients will experience adverse drug events. The method provides personalized patient dose suggestions, drug administration frequency, and drug selection suggestions.
Owner:THE RGT UNIV OF MICHIGAN
Bupropion dosage forms with reduced food and alcohol dosing effects
PendingUS20250262202A1Nervous disorderHydroxy compound active ingredientsIngested foodTreatment-resistant depression
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Use of r-ketamine in treatment of depression accompanied by acute suicidal ideation or behavior
PCT designated stageWO2025256585A1Organic active ingredientsNervous disorderEfficacyPharmaceutical drug
A use of R-ketamine in the treatment of depression accompanied by acute suicidal ideation or behavior. Specifically, a use of R-ketamine or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same in the preparation of a medicament for treating depression accompanied by acute suicidal ideation or behavior. The depression may be treatment-resistant depression (TRD) or major depressive disorder (MDD). By means of intravenous injection of an effective dose of R-ketamine hydrochloride, it is found that the efficacy of administering R-ketamine hydrochloride is better than the efficacy of administering the same dose of S-ketamine hydrochloride, that is, a rapid antidepressant effect is achieved, the efficacy lag can be significantly shortened, the suicidal ideation or behavior of patients is significantly reduced, and the risk of suicide is quickly alleviated.
Owner:NHWA PHARMA CORPORATION
Methods For The Treatment Of Depression
The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and / or for the treatment and / or prevention of suicidality (e.g. suicidal ideations).
Owner:JANSSEN PHARMA NV
Subcutaneous formulations comprising psilocybin derivatives
PendingUS20260021070A1Organic active ingredientsNervous disorderSubcutaneous injectionNeuropsychiatric disease
The present disclosure provides stable liquid formulations comprising Compound 1, or a pharmaceutically acceptable salt of Compound 1, and one or more pharmaceutically acceptable excipients. The liquid formulation may comprise a pH buffered aqueous solution, and optionally a pH modifier and / or a tonicity agent. Also provided herein are methods of delivering the formulation via parenteral administration (e.g., subcutaneous injection), and methods of using the formulation in the treatment of neuropsychiatric diseases (e.g., treatment resistant depression).
Owner:COMPASS PATHFINDER LTD
Methods of treatment using mtorc1 modulator
To provide methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.SOLUTION: The present invention provides, inter alia, methods of treating depression comprising administering to a patient in need thereof a therapeutically effective amount of ((S)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid), or a pharmaceutically acceptable salt or composition thereof. In some embodiments, the depression is major depressive disorder (MDD). In some embodiments, the depression is treatment-resistant depression (TRD).SELECTED DRAWING: None
Owner:NAVITOR PHARMACEUTICALS INC
Treatment or Reversal of Treatment Resistant Depression and Related Central Nervous System (CNS) Inflammatory Conditions with a JAK Inhibitor
This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.
Owner:EMORY UNIVERSITY
A synergistic neuromodulation system for treatment-resistant depression
The application discloses a kind of synergic neuromodulation systems for refractory depression, it is related to neuromodulation technical field, including: obtaining individual historical conversation data to establish reference quantity, collect cortical physiology and salivary cortisol data to calculate cortical inhibition proxy quantity and axis drive proxy quantity;The above proxy quantity is standardized based on individual reference quantity and generates continuous flip point intensity;According to flip point intensity, the total stimulation load benchmark is continuously distributed as cortical stimulation component load and vagus-related regulation component load, and each component load is mapped into synergic control instruction to drive equipment to execute stimulation.The application quantifies physiological state and adaptively distributes load, avoids the reversal of stimulation effect under specific state, and improves treatment stability.
Owner:樊亚会
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC